網友分享亚洲高清国产拍精品影院心得_护士高潮的放荡毛片视频_亚洲欧洲在线观看AV黄_亚洲日本va中文字幕无_亚洲永久免费播放片_国产高清无码91zx_久久青青视频黄色一级_免费不卡的av电影_喷潮白浆直流在线播放_99re这里只有精品大香伊


TEL:17312606166(魏經(jīng)理)

VR圖標(biāo)白色 VR圖標(biāo)黑色
X

美鳳力臨床前大動物實(shí)驗(yàn)中心

與我們?nèi)〉寐?lián)系

    17312606166

Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases:Steatosis, NASH and Fibrosis

昆明,中國,2017年10月15日

CONTROL ID:2776800
PRESENTATION TYPE:Poster Only
CURRENT CATEGORY:Steatosis and Steatohepatitis
CURRENT DESCRIPTORS:SO1. Steatohepatitis: Experimental
TITLE:Development and Characterization of High Fat Diet-induced Non-human Primate Models of Liver Diseases:Steatosis, NASH and Fibrosis
AUTHORS (FIRST NAME, LAST NAME):Lichuan Yang1, Joseph Gabriel1, Zhenghua Zhu1, Feng Li1, Yuchao Zhao1, Guanzhong Wang1, Rosario Perez1, Shaodong Li1, Tony Wang1, Bob Zhang1
Oral/Poster: Institutional Author(s):(none)
INSTITUTIONS (ALL):
1. Kunming Biomed International, Kunming, Yunnan, China.


ABSTRACT BODY:
Abstract Body:Background: Lack of translatable animal models is a major challenge for developing nonalcoholic steatohepatitis (NASH) therapies. This study aims to develop a large colony of high fat diet (HFD)-induced nonhuman primate (NHP) liver disease models to facilitate new NASH drug discovery.

Methods: Over 1,500 male cynolmolgus monkeys were fed with HFD over 2-6 years. Metabolic syndrome phenotypes and diabetes progression were monitored longitudinally by body weight, IVGTT, BP and clinical chemistry. Liver steatosis was measured by ultrasound liver scan and quantitated by MRI. MRI assessment was validated by liver biopsy and hepatic triglyceride (TG). NASH was assessed by histological analysis of liver biopsy after HE staining. Liver fibrosis was evaluated by ultrasound elastography for stiffness (kPa) and biopsy after Sirius Red staining. NAFLD activity score (NAS) and fibrosis score (FS) were generated by the scale from NASH Clinical Research
Network.

Results: Majority of HFD-fed monkey colony developed metabolic syndrome phenotypes, as well as diabetes and diabetic complications. MRI liver fat fraction (FF) measurements performed in a representative cohort of 33 HFD-fed monkeys showed that 18 monkeys (55%) had FF >5% (cutoff value for steatosis), with average of 12.4±5.5%; while 10 normal monkeys had FF value of 2.7±0.6%. MRI FF levels correlated well with Oil Red O and HE staining of liver biopsies and hepatic TG levels (R2=0.85, p<0.05; n=12). Limited liver biopsy on monkeys (N=62) demonstrated 40 monkeys (64%) had NASH phenotype (NAS score of 4-7), including severe steatosis, moderate ballooning, and lobular inflammation. 20 of these NASH monkeys (32%) showed perisinusoidal/portal/periportal/bridge fibrosis (FS scores 1-3). Ultrasound elastography showed higher liver stiffness in NASH monkeys (kPa=4.79±1.09, n=10) compared to normal monkeys (kPa=1.14±0.25, n=10; p<0.009). 4 of 10 NASH monkeys had kPa >7.7 (cutoff value for human fibrosis). Their fibrosis stages were confirmed by liver biopsy.

Conclusion: HFD-induced NHP liver disease models have been developed and characterized in a large cohort. They have similar disease progression and pathological features seen in humans. Based on limited MRI and liver biopsy data, it is estimated that 55% of monkeys on HFD diet have steatosis (>800), 64% of steatosis monkeys have NASH (>500) and 32% of NASH monkeys have fibrosis (>150). These models have potential translational values for therapeutic evaluation of anti-NASH agents.
(no table selected)
(No Image Selected)
Co-Author Disclosure Status

The following authors have completed their AASLD 2017 disclosure:Lichuan Yang: Disclosure completed | Joseph Gabriel: Disclosure completed | Zhenghua Zhu: Disclosure completed | Feng Li: Disclosure completed | Yuchao Zhao: Disclosure completed | Guanzhong Wang: Disclosure completed | Rosario Perez: Disclosure completed | Shaodong Li: Disclosure completed | Tony Wang: Disclosure completed | Bob Zhang: Disclosure completed

AASLD 2017 poster 2017-10-05.jpg

AASLD 2017 poster 2017-10-05.jpg

上一篇:魏輔文院士應(yīng)邀出席生物多樣性公約第14屆締約方大會并做主旨發(fā)言 下一篇:中國科學(xué)院生物標(biāo)本館(博物館)2018年度工作會議在動物研究所舉行

TAG標(biāo)簽:

美鳳力借多年的大動物經(jīng)驗(yàn),堅(jiān)持以“務(wù)實(shí)求真”為宗旨,累計(jì)為4000多家客戶提供品質(zhì)大動物臨床前服務(wù),得到了客戶的一致好評。如果您有動物試驗(yàn)、臨床培訓(xùn)、組織病理、大動物試驗(yàn)、臨床試驗(yàn)、產(chǎn)品注冊科研課題等...
請立即點(diǎn)擊咨詢我們或撥打咨詢熱線: 17312606166 ,我們會詳細(xì)為你一一解答你心中的疑難。
添加好友

相關(guān)閱讀 更多>>

猜您喜歡更多>>